So far, the most promising results for breast cancer have been obtained with the broad-spectrum anti-FZD antibody OMP-18R5/vantictumab, which blocks FZD1, 2, 5, 7, and 8 (Gurney et al., 2012). The gene discussed is FZD1; the disease is breast carcinoma.